Similarly, antibodies targeting LILRB1 and LILRB2 alone or in combination with PD-1 blockade have been shown to reinvigorate tumor immunity and are being assessed in early-phase clinical trials with encouraging initial results [100,101,102]. The gene discussed is LILRB1; the disease is neoplasm.